A phase I clinical trial of the anti-GPC3 monoclonal antibodies, codrituzumab combined with atezolizumab, demonstrated not only good tolerance of the agents but also significant suppression of tumor growth in patients with advanced HCC. This evidence concerns the gene GPC3 and hepatocellular carcinoma.